PLGA Acid Capped (PLGA-COOH, 50:50)

Price range: $120.00 through $720.00

PLGA Acid Capped (PLGA-COOH, 50:50) is a biodegradable poly(lactide-co-glycolide) copolymer with a 50:50 lactide ratio and a terminal carboxylic acid (COOH) group. The free carboxyl end group enables efficient bioconjugation and chemical modification, while the 50:50 composition provides one of the fastest degradation rates among PLGA copolymers. PLGA-COOH (50:50) is widely used in nanoparticle formulation, controlled drug delivery, tissue engineering, and biomaterials research.

Product Name: PLGA Acid Capped (PLGA-COOH, 50:50)
Alternative Name: Carboxyl-Terminated PLGA (50:50), PLGA-COOH (50:50)
Polymer Type: Poly(D,L-lactide-co-glycolide)
Lactide Ratio: 50:50
Molecular Weight: 2k, 5k, 10k, 15k, 20k, 30k, 50k, 100k Da, Custom
End Group: Carboxylic Acid (COOH)
Appearance: White to off-white powder or solid
Solubility: Dichloromethane, Chloroform, THF, Acetone, DMF, DMSO
Storage: -20°C, dry and protected from moisture
Purity: Typically ≥99%

 

Description

General Description

PLGA Acid Capped (PLGA-COOH, 50:50) is a carboxyl-terminated biodegradable polyester composed of equal molar ratios of lactide and glycolide. Among commonly available PLGA compositions, the 50:50 ratio exhibits the fastest hydrolytic degradation due to its balanced copolymer composition, making it particularly suitable for short- to medium-term controlled drug release applications.

The terminal carboxylic acid group serves as a versatile reactive handle for conjugation with polyethylene glycol (PEG), peptides, proteins, antibodies, fluorophores, targeting ligands, and other bioactive molecules using carbodiimide (EDC/NHS) chemistry. As a result, PLGA-COOH (50:50) is frequently used as a precursor for functional PLGA derivatives and targeted drug delivery systems.

PLGA Acid Capped (50:50) is extensively employed in polymeric nanoparticles, microspheres, injectable depots, tissue engineering scaffolds, biodegradable implants, and controlled-release formulations.

Applications

  • Controlled drug delivery
  • Nanoparticle formulation
  • Microsphere preparation
  • Injectable depot systems
  • PEG conjugation
  • Protein conjugation
  • Tissue engineering
  • Surface modification
  • Biomaterials development
  • Biomedical research

Features and Benefits

  • Terminal carboxylic acid functionality
  • 50:50 lactide composition
  • Fast degradation profile
  • Efficient EDC/NHS coupling
  • Excellent drug encapsulation capability
  • Excellent biocompatibility
  • Suitable for targeted polymer conjugates
  • Available in multiple molecular weights
  • Ideal precursor for PLGA derivatives

Additional information

Molecular weight

2K, 5K, 10K, 15K, 20K, 30K, 40K, 80K, 160K

Package size

1g, 5g, 10g